Cisplatin and Vinorelbine for Malignant Pleural Mesothelioma
Author Information
Author(s): Sørensen J B, Frank H, Palshof T
Primary Institution: National University Hospital, Copenhagen, Denmark
Hypothesis
The study aims to evaluate the activity of cisplatin and vinorelbine in previously untreated, inoperable patients with malignant pleural mesothelioma.
Conclusion
Cisplatin and intravenous vinorelbine is a highly active regimen in malignant pleural mesothelioma with a response rate and survival comparable to the most active regimens reported.
Supporting Evidence
- Median overall survival was 16.8 months.
- 61% of patients were alive after 1 year.
- 29.6% response rate was observed in the study.
Takeaway
This study tested a combination of two drugs, cisplatin and vinorelbine, to help patients with a serious lung cancer called malignant pleural mesothelioma, and it showed that the treatment can help some patients live longer.
Methodology
Patients received vinorelbine 25 mg/m² intravenously weekly and cisplatin 100 mg/m² intravenously every 4 weeks, with hydration and standard prophylactic antiemetic treatment.
Potential Biases
Potential selection biases in the choice of second-line treatment.
Limitations
The study was not a formal phase II trial and had a relatively small sample size.
Participant Demographics
85% male, median age 63 years, 74% epithelial subtype, 81% in IMIG stages III and IV.
Statistical Information
Confidence Interval
95% confidence limits 18.0–43.6%
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website